#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	51	14568	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2274	765.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1447	1447	C	910	C,A	908,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24498	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4113	743.1	0	.	n	.	0	T695C	SNP	695	695	T	1266	1266	C	920	C,A,T	916,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24498	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4113	743.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1908	1908	A	970	A,G	969,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24498	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4113	743.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2542	2542	C	829	C,G,T	827,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24498	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4113	743.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2616	2616	A	771	A,T	770,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24498	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4113	743.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3168	3168	C	902	C	902	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	1900	folP	855	855	100.0	folP.l15.c4.ctg.1	1988	119.4	1	SNP	p	R229S	1	.	.	685	687	AGC	1238	1240	AGC	194;196;198	A;G;C,A	194;196;197,1	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4188	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3946	132.5	1	SNP	p	S91F	1	.	.	271	273	TTC	888	890	TTC	150;147;147	T;T;C	150;147;147	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4188	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3946	132.5	1	SNP	p	G95N	0	.	.	283	285	GGC	900	902	GGC	151;151;150	G;G;C,G	151;151;149,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4188	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3946	132.5	1	SNP	p	D95G	1	.	.	283	285	GGC	900	902	GGC	151;151;150	G;G;C,G	151;151;149,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1838	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1929	118.8	1	SNP	p	G45D	0	.	.	133	135	GGC	796	798	GGC	196;197;196	G,C;G;C	195,1;197;196	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	952	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1469	80.4	0	.	n	.	0	A197.	DEL	197	197	A	834	834	A	202	A	202	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4408	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3517	156.3	1	SNP	p	D86N	0	.	.	256	258	GAC	874	876	GAC	200;201;198	G;A;C	200;201;198	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4408	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3517	156.3	1	SNP	p	R87I	0	.	.	259	261	CGT	877	879	CGT	200;203;204	C;G;T	200;203;204	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4408	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3517	156.3	1	SNP	p	S87R	1	.	.	259	261	CGT	877	879	CGT	200;203;204	C;G;T	200;203;204	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4408	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3517	156.3	1	SNP	p	R87W	0	.	.	259	261	CGT	877	879	CGT	200;203;204	C;G;T	200;203;204	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4408	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3517	156.3	1	SNP	p	S88P	0	.	.	262	264	TCC	880	882	TCC	203;202;204	T;C;C	203;202;204	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3810	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3288	144.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1835	1837	GGC	207;205;204	G,A;G;C	206,1;205;204	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	3538	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2925	150.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1510	1512	GCA	234;237;241	G,T,A;C,A;A	232,1,1;236,1;241	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3538	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2925	150.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1513	1515	ATC	241;239;239	A;T,A;C,A	241;238,1;237,2	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3538	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2925	150.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1525	1527	GTG	249;248;250	G;T;G	249;248;250	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3538	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2925	150.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1525	1527	GTG	249;248;250	G;T;G	249;248;250	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3538	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2925	150.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2029	2031	ACC	226;224;227	A;C;C	226;224;227	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3538	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2925	150.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2083	2085	GCG	199;200;202	G,C;C,T;G	198,1;199,1;202	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3538	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2925	150.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2083	2085	GCG	199;200;202	G,C;C,T;G	198,1;199,1;202	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3538	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2925	150.8	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2206	2208	AGC	168;168;167	A,C;G;C	167,1;168;167	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3538	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2925	150.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2215	2217	GGC	161;161;164	G;G;C	161;161;164	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3538	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2925	150.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2233	2235	CCG	184;186;187	C;C,T;GCCC,GCC	184;185,1;181,1	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5048	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3648	172.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1937	1939	CCG	222;224;224	C,G;C;G	221,1;224;224	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2270	porA	1146	1146	99.91	porA.l15.c17.ctg.1	2361	119.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	879	879	C	154	C	154	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	304	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	283	22.1	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	19;20;22	T;T;A	19;20;22	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	304	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	283	22.1	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	48;48;48	C;A;T	48;48;48	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	304	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	283	22.1	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	48;48;48	A;G;T	48;48;48	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	304	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	283	22.1	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	48;48;48	T;A;C,T	48;48;47,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	304	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	283	22.1	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	304	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	283	22.1	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	304	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	283	22.1	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	2;2;2	G;A;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	304	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	283	22.1	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	2;2;2	A;T;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	304	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	283	22.1	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	2;2;2	T;C;G	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	304	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	283	22.1	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	304	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	283	22.1	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	2;2;2	A;G;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	304	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	283	22.1	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	304	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	283	22.1	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	304	porB1a	984	100	94.0	porB1a.l15.c17.ctg.4	182	63.2	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	74;70;67	A;C;G	74;70;67	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	304	porB1a	984	100	94.0	porB1a.l15.c17.ctg.4	182	63.2	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	26;25;22	C;A;A	26;25;22	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3030	porB1b	1047	1047	99.43	porB1b.l15.c17.ctg.1	1805	205.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	525	527	GAA	254;254;254	G,C;A;A	253,1;254;254	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3030	porB1b	1047	1047	99.43	porB1b.l15.c17.ctg.1	1805	205.6	0	.	p	.	0	V47M	NONSYN	139	141	GTG	552	554	ATG	240;243;246	A;T,A,C;G	240;241,1,1;246	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3030	porB1b	1047	1047	99.43	porB1b.l15.c17.ctg.1	1805	205.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	936	938	TCA	267;266;268	T,G;C,G;A	266,1;265,1;268	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3030	porB1b	1047	1047	99.43	porB1b.l15.c17.ctg.1	1805	205.6	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1395	1397	GCA	220;220;217	G;C,T,A;A	220;218,1,1;217	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3030	porB1b	1047	1047	99.43	porB1b.l15.c17.ctg.1	1805	205.6	1	SNP	p	G120K	1	.	.	358	360	AAG	771	773	AAG	287;285;284	A,C;A,T,C;G	286,1;283,1,1;283	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3030	porB1b	1047	1047	99.43	porB1b.l15.c17.ctg.1	1805	205.6	1	SNP	p	A121D	1	.	.	361	363	GAC	774	776	GAC	283;281;282	G;A,C;C	282;279,1;281	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3030	porB1b	1047	1047	99.43	porB1b.l15.c17.ctg.1	1805	205.6	1	SNP	p	D121N	0	.	.	361	363	GAC	774	776	GAC	283;281;282	G;A,C;C	282;279,1;281	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10112	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5402	233.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1552	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1517	127.1	1	SNP	p	V57M	1	.	.	169	171	ATG	727	729	ATG	265;261;262	A;T;G	265;261;262	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
